Another approach for PSMA-specific targeting is based on engineered T cells expressing chimeric anti-PSMA immunoglobulin-T-cell-receptor constructs which were shown to specifically lyse PSMA-expressing PCa cells and retard tumor growth in a mouse xenograft model [64]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.